209285-92-7 Usage
Uses
Used in Organic Synthesis:
7-(bromomethyl)-1-chloroisoquinoline is used as a building block in organic synthesis for the creation of various biologically active molecules and pharmaceuticals. Its unique structure allows for the development of complex organic compounds with potential applications in different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 7-(bromomethyl)-1-chloroisoquinoline serves as a key intermediate in the synthesis of new drugs. Its presence in the molecular structure can contribute to the desired pharmacological properties, making it a valuable component in drug discovery and development.
Used in Materials Science:
7-(bromomethyl)-1-chloroisoquinoline is utilized in the development of new materials, thanks to its chemical properties and reactivity. It can be incorporated into the design and synthesis of advanced materials with specific characteristics, such as improved stability or enhanced performance in various applications.
Used as a Precursor in Chemical Research:
As a precursor, 7-(bromomethyl)-1-chloroisoquinoline plays a crucial role in chemical research, enabling the synthesis of complex organic compounds. Its versatility and reactivity make it an essential component in the exploration of new chemical reactions and the development of innovative synthetic pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 209285-92-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,9,2,8 and 5 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 209285-92:
(8*2)+(7*0)+(6*9)+(5*2)+(4*8)+(3*5)+(2*9)+(1*2)=147
147 % 10 = 7
So 209285-92-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H7BrClN/c11-6-7-1-2-8-3-4-13-10(12)9(8)5-7/h1-5H,6H2
209285-92-7Relevant academic research and scientific papers
Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
-
, (2008/06/13)
The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.
Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor Xa.
Choi-Sledeski,Becker,Green,Davis,Ewing,Mason,Ly,Spada,Liang,Cheney,Barton,Chu,Brown,Colussi,Bentley,Leadley,Dunwiddie,Pauls
, p. 2539 - 2544 (2007/10/03)
The design, synthesis and SAR of sulfonamidopyrrolidinone fXa inhibitors incorporating a new benzamidine isostere, namely aminoisoquinolines, is described. These inhibitors have higher Caco-2 cell permeability than comparable benzamidines and attain higher levels of exposure upon oral dosing. The most potent member 14b (fXa Ki=6 nM) is selective against other serine proteasesof interest (>600 fold).
